Open AccessSerum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study
Author(s) -
Uzawa A.,
Kojima Y.,
Ozawa Y.,
Yasuda M.,
Onishi Y.,
Akamine H.,
Kawaguchi N.,
Himuro K.,
Kuwabara S.
Publication year - 2020
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/cei.13499
Subject(s) - supar , myasthenia gravis , autoantibody , immunology , medicine , biomarker , antibody , acetylcholine receptor , autoimmune disease , urokinase , receptor , gastroenterology , endocrinology , urokinase receptor , biology , biochemistry
Serum suPAR levels can be a candidate for a novel biomarker of disease activity in anti‐acetylcholine receptor antibody‐positive MG.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom